Treatment News : For People With HIV, Livalo Lowers LDL Better Than Pravachol

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 7, 2013

For People With HIV, Livalo Lowers LDL Better Than Pravachol

CROI 2013The statin medication Livalo (pitavastatin) is more effective at lowering LDL (“bad”) cholesterol in HIV-positive adults with high cholesterol than another drug in the same class, Pravachol (pravastatin). Kowa Pharmaceuticals America Inc. and Eli Lilly and Company announced the findings of their 12-week, Phase IV, double-blind study at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta. In the study, 252 HIV-positive participants, both with and without hepatitis B or C, were randomized one-to-one to receive a daily dose of either 4 mg of Livalo or 40 mg of Pravachol. The primary end point of the study was the percentage drop in LDL cholesterol.  

After 12 weeks of therapy, those taking Livalo saw an average drop in LDL cholesterol of 31 percent, compared with a 21 percent drop in the group taking Pravachol, a difference that was statistically significant, meaning it was too great to have occurred by chance. The percentage of participants experiencing adverse events was similar between the two groups, with 61.1 percent for Livalo and 62.7 percent for Pravachol. The most common adverse events overall included diarrhea, upper respiratory tract infection, sinusitis, headache, nausea, nasal and pharynx inflammation (nasopharyngitis) and an increase in blood creatine phosphokinase. Eleven subjects (4 percent) left the study because of adverse events.

To read the Eli Lilly release, click here.

Search: Livalo, pitavastatin, statin, cholesterol, LDL, Kowa Pharmaceuticals America, Eli Lilly and Company, 20th Conference on Retroviruses and Opportunistic Infections, CROI.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (2 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dhsd777
    san diego
    California


    slimcuteguy
    Asheville
    North Carolina


    hollywoodvers1
    Los Angeles
    California


    HOTROD2010
    houston
    Texas
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.